SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias

Phase 2 Withdrawn Abfero Pharmaceuticals, Inc

Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to test the safety and tolerability of SP-420 and it's efficacy in terms of lowering iron in subjects with Beta-thalassemia or other rare anemias who need regular blood transfusions.

Timeline

Start: 2020-08
Primary completion: 2022-09
Completion: 2023-01

Outcome

Outcome not reported

Stopped (Enrollment): “Protocol suspended prior to patient enrollment”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SP-420	Small molecule	28 mg/kg	Oral
Subject	SP-420	Small molecule	56 mg/kg	Oral
Subject	SP-420	Small molecule	84 mg/kg	Oral

SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias

Summary

Timeline

Outcome

Drugs

Indications